Anuh Pharma Limited has informed the Exchange regarding 'appointment of Internal Auditor'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma's Board approved FY2026 audited results: revenue of Rs. 7,717 crore (up 17% YoY) and net profit of Rs. 410.5 crore (down 13% YoY), with EBITDA margin at 8.56% vs 10.64% prior year, impacted by mark-to-market losses and forex headwinds. The Board recommended a dividend of Rs. 1.50 per share (30% payout), subject to shareholder approval at the AGM on 12th August 2026. Nine promoter group shareholders (totaling 0.95% stake) have sought re-classification from 'Promoter Group' to 'Public' category under SEBI LODR Regulation 31A. Key appointments include M/s. RMJ & Associates LLP as Internal Auditor and Mr. P.N. Rao as General Manager – Quality (w.e.f. 1st June 2026). Two directors — Mr. Bipin Shah and Mr. Arun Todarwal — were re-appointed as directors liable to retire by rotation. A bonus issue (1:1) was implemented in July 2025, doubling the paid-up capital to Rs. 5,011.20 lakh.
Promoter group re-classification request for ~0.95% stake could signal dilution of promoter control; declining profit despite higher revenue raises margin concerns, though dividend offer provides investor support.